Advertisement
Advertisement
U.S. markets open in 4 hours 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Adverum Biotechnologies, Inc. (ADVM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
1.5500-0.0600 (-3.73%)
At close: 04:00PM EDT
1.5300 -0.02 (-1.29%)
After hours: 05:51PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close1.6100
Open1.5600
Bid0.0000 x 2200
Ask0.0000 x 800
Day's Range1.4505 - 1.5836
52 Week Range0.5310 - 2.3400
Volume110,773
Avg. Volume452,523
Market Cap162.598M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-1.3400
Earnings DateNov 08, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADVM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adverum Biotechnologies, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/25/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Adverum Biotechnologies to Participate in Upcoming Investor Conferences

    REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 8:00 a.m. ET.Chardan’s 7th Annual Genetics Medicines Conference on Monday, Octo

  • GlobeNewswire

    Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

    REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023. The on-demand webcast corporate presentation may be accessed under Event

  • GlobeNewswire

    Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer

    Dr. Ramelmeier has more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including gene and cell therapiesREDWOOD CITY, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s ch

Advertisement
Advertisement